APA (7th ed.) Citation

Xu, J., Li, Y., Fan, Q., Shu, Y., Yang, L., Cui, T., . . . Mancao, C. (2022). Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: A randomized, open-label phase 2 study (ORIENT-2). Nature communications, 13(1), 857-12. https://doi.org/10.1038/s41467-022-28408-3

Chicago Style (17th ed.) Citation

Xu, Jianming, et al. "Clinical and Biomarker Analyses of Sintilimab Versus Chemotherapy as Second-line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Randomized, Open-label Phase 2 Study (ORIENT-2)." Nature Communications 13, no. 1 (2022): 857-12. https://doi.org/10.1038/s41467-022-28408-3.

MLA (9th ed.) Citation

Xu, Jianming, et al. "Clinical and Biomarker Analyses of Sintilimab Versus Chemotherapy as Second-line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Randomized, Open-label Phase 2 Study (ORIENT-2)." Nature Communications, vol. 13, no. 1, 2022, pp. 857-12, https://doi.org/10.1038/s41467-022-28408-3.